Matt Luther, MD MSCI's Avatar

Matt Luther, MD MSCI

@drjmluther.bsky.social

Nephrologist, Hypertension specialist, Physician-scientist.

920 Followers  |  582 Following  |  124 Posts  |  Joined: 13.11.2024  |  2.6666

Latest posts by drjmluther.bsky.social on Bluesky

Tolerate if really needed, but taper as BP falls after spironolactone takes effect- usually weeks to 3 months

28.09.2025 04:37 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

42% sensitivity is what you want in a screening test, right? [sarcasm]

24.09.2025 15:03 โ€” ๐Ÿ‘ 6    ๐Ÿ” 1    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0
Lithuanian copy of Hypertension Secrets

Lithuanian copy of Hypertension Secrets

Hypertension Secrets has been translated into multiple languages, including Lithuanian!

Get your copy here: shop.elsevier.com/books/hypert...

@edgarvlermamd.bsky.social @drjmluther.bsky.social

17.09.2025 16:07 โ€” ๐Ÿ‘ 9    ๐Ÿ” 2    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Post image

The CPC from last @ahascience.bsky.social #HypertensionSessions now published in @ahajournals.bsky.social

www.ahajournals.org/doi/10.1161/...

thanks to @drjmluther.bsky.social and all the education editors for the invite

We hope it makes for an educational read!

20.08.2025 18:09 โ€” ๐Ÿ‘ 12    ๐Ÿ” 7    ๐Ÿ’ฌ 3    ๐Ÿ“Œ 0
Preview
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College o...

New 2025 AHA/ACC Hypertension Guideline dropped!

www.jacc.org/doi/10.1016/...

#hypertension #medsky #nephsky

14.08.2025 18:06 โ€” ๐Ÿ‘ 24    ๐Ÿ” 13    ๐Ÿ’ฌ 5    ๐Ÿ“Œ 0
Preview
Treatment of hypertension - Lasker Foundation Explore All 1957 Winners & Awards > Rustom Jal VakilKing Edward VII Memorial Hospital, Bombay For studies on the use of reserpine in the treatment of hypertension. The story of Rauwolfiaโ€ฆ

#LaskerLaureate Rustom Jal Vakil was born #OTD in 1911. He won a #LaskerAward in 1957 for his studies on the use of reserpine in the treatment of #hypertension. ow.ly/bFTR50FunRI ๐Ÿงช

17.07.2025 14:06 โ€” ๐Ÿ‘ 4    ๐Ÿ” 3    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0

almost always lower dose 12.5-25, occasionally higher 50-100mg.
hyperkalemia/CKD > gynecomastia > dysmenorrhea of course can be limiting

15.07.2025 16:45 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Post image

Yes you should be able to reduce medications after adding Spironolactone.
I withdraw based on other adverse med effects (edema = CCB; K = thiazide/RAASi)

I use this figure in my talks on Resistant HTN...(observational, but holds up imo)

pubmed.ncbi.nlm.nih.gov/11991219/

15.07.2025 16:16 โ€” ๐Ÿ‘ 4    ๐Ÿ” 1    ๐Ÿ’ฌ 3    ๐Ÿ“Œ 0
Preview
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline AbstractBackground. Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a

New PA Endo guideline is also out by experts @anandvaidya17.bsky.social #Cardiosky @hswapnil.medsky.social doi.org/10.1210/clin...

14.07.2025 18:56 โ€” ๐Ÿ‘ 22    ๐Ÿ” 14    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.

Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.

The first #ERA25 simultaneous pub

CONFIDENCE trial of empagliflozin + finerenone in N = 579

Greater reduction in ACR and BP
Note the impressive GFR dip

www.nejm.org/doi/full/10....

05.06.2025 09:54 โ€” ๐Ÿ‘ 40    ๐Ÿ” 24    ๐Ÿ’ฌ 4    ๐Ÿ“Œ 0

Bring back methyldopa too!

30.05.2025 02:41 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Standardized treatment in advance-HTN included thiazide + ARB for all.

Upcoming Launch-HTN uses standard background meds so will be a mix of real world regimens.
Longer term open label followup is ongoing too.

30.05.2025 02:40 โ€” ๐Ÿ‘ 3    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

I'm gonna guess Geriatrics

29.05.2025 21:06 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
old drugs in HT

old drugs in HT

Plenary at @hypertensioncanada.bsky.social with @drjmluther.bsky.social on new drugs

He starts of with the really old drugs!

#CHC25

29.05.2025 14:11 โ€” ๐Ÿ‘ 12    ๐Ÿ” 4    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0

*in rodents

29.05.2025 01:08 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension This randomized clinical trial examines the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication in adult patients with uncontrolled hypertension.

Phase 2 trial of the new antihypertensive agent, ultra-long-acting (q6 month), subq, small interfering RNA against angiotensinogen (Zilebesiran), hit JAMA!

h/t @drjmluther.bsky.social

jamanetwork.com/journals/jam...

1/

28.05.2025 20:09 โ€” ๐Ÿ‘ 15    ๐Ÿ” 8    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0

Hyponatremia define here as <135, and also while all patients on a thiazide. Suspect clinically significant hypoNa is much less common.
#NephJC

28.05.2025 17:40 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

I do not have any inside info- doesn't look like it is being studied in the US, likely due to lack of patent protection. But it appears much less selective than newer agents. It is just R-fadrazole.

28.05.2025 03:38 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

the bigger issue is - don't block cortisol synthesis, which ramps up ACTH and revs up the steroid pathway and further augments DOC accumulation.
#NephJC

btw @kidneyboy.bsky.social this pathway needs to be taught to our Neph fellows so they can think this problem out like you're doing

28.05.2025 02:11 โ€” ๐Ÿ‘ 8    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Indapamide 2.5mg or if previously on HCTZ continue that dose (if I recall correctly).
Plus Olmesartan 40mg in all.
If previously on 3 drugs then Amlodipine 10mg or max tolerated dose used.
#NephJC

28.05.2025 02:08 โ€” ๐Ÿ‘ 2    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

absolutely.

28.05.2025 02:02 โ€” ๐Ÿ‘ 2    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Not sure the numbers are sig different, but I think your rationale is correct. The dose would have been pushed up to 100mg only in the most resistant #NephJC

28.05.2025 01:57 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Theoretically:
- it targets the primary issue in many patients- unregulated aldosterone production.
-avoid effect of further elevated Aldo during MRA treatment

Obvs -avoid gynecomastia and off-target effects of Spiro.
For other MRAs it has always been difficult to push dose high enough.
#NephJC

28.05.2025 01:54 โ€” ๐Ÿ‘ 10    ๐Ÿ” 3    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0

I would classify Osilodrostat as a nonselective inhibitor. It impaired Cort-stim response in those doses. also Lowered BP - would not include with selective ASIs.

Osilodrostat is now approved for treatment of Cushing's (Cortisol inhibition) at much higher dose than used in these trials.
#NephJC

28.05.2025 01:50 โ€” ๐Ÿ‘ 9    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

That is why they added the Cystatin-C measurement to help clarify.
I do expect some hemodynamic effect with treatment of uncontrolled HTN into a lower range, though.
#NephJC

28.05.2025 01:45 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

correct. Aldo usually increases with MRA treatment.
Renin increases during both ASI and MRA.

Plasma Aldo provides a snapshot in time.
24hr urine Aldo may give a better measure of coverage.
#NephJC

28.05.2025 01:42 โ€” ๐Ÿ‘ 9    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

At very high dose, ASIs increase DOC.
Less potent MR agonist - BP reduction and Renin increase is still evident.
CYP11B1 inhibition also increases ACTH, DOC.
Lower dose for each ASI is chosen in part to limit DOC response.
#NephJC

28.05.2025 01:39 โ€” ๐Ÿ‘ 8    ๐Ÿ” 2    ๐Ÿ’ฌ 2    ๐Ÿ“Œ 0
Post image

Baxdrostat HALO study failed to reach primary endpoint - I don't know why but VERY large placebo drop in AOBP.
Trial design or conduct error. I don't think it was the drug.
#NephJC

28.05.2025 01:32 โ€” ๐Ÿ‘ 4    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Still early, safety first.
Hyponatremia defined as <135 was very annoying to me since most of my patients live at 130-135 on a thiazide.
#nephJC

28.05.2025 01:24 โ€” ๐Ÿ‘ 5    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

As data emerges, the 3 new agents are much more selective than prior drugs. Still need more data on Vicadrostat (done but not shown in publications).
#nephJC

28.05.2025 01:23 โ€” ๐Ÿ‘ 10    ๐Ÿ” 9    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 1

@drjmluther is following 19 prominent accounts